Background: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab [(Opdivo)], an anti-PD-1 antibody, in these patients. Methods: This was a multicentre, … [Read more...]
Bristol’s Opdivo scores again in tough-to-treat mesothelioma, this time flying solo
Last year at the World Conference on Lung Cancer, Bristol Myers Squibb made waves in mesothelioma with data showing its Opdivo – Yervoy duo could slash the risk of death in previously untreated patients. This year, it grabbed the spotlight with another survival win in the tough-to-treat disease. Saturday, solo Opdivo became the first med to show … [Read more...]
Nivolumab/Ipilimumab Demonstrates Durable OS Benefit in Malignant Pleural Mesothelioma
Nivolumab (Opdivo) plus ipilimumab (Yervoy) significantly improved overall survival (OS) versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma, according to findings from a prespecified analysis of the phase 3 CheckMate-743 trial (NCT02899299) that were presented during the 2020 International … [Read more...]